NICE
NICE recommends Novartis’ ribociclib in combination with fulvestrant for breast cancer
February 26, 2021Medical Communications Cancer, NICE, Novartis
NICE has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior endocrine therapy. It will be made …
NICE issues draft guidance recommending sapropterin for PKU in children
February 25, 2021BioMarin, NICE, PKU
NICE has issued draft guidance which recommends BioMarin’s Kuvan (sapropterin) at a dose of up to 10 mg/kg for treating phenylketonuria …
NICE recommends Bristol Myers Squibb’s skin cancer drug Opdivo for NHS use
February 12, 2021Medical Communications Bristol-Myers Squibb, NICE, bristol myers squibb
NICE has issued final draft guidance recommending the routine use of Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) as an option …
NICE recommends treatments for pregnancy sickness in new draft guidance
February 11, 2021NICE, Pregnant
NICE has recommended treatment options for severe pregnancy sickness for the first time, issuing recommendations in draft guidance published today.
NICE rejects multiple sclerosis drug Zeposia
January 22, 2021Medical Communications NICE
NICE has decided not to recommend Bristol Myers Squibb’s Zeposia (ozanimod) for the treatment of relapsing/remitting multiple sclerosis (RRMS). In …
NICE recommends rheumatoid arthritis drug Jyseleca for NHS use
January 21, 2021Gilead, NICE
NICE has issued a final appraisal determination (FAD) recommending the use of Jyseleca (filgotinib) on the NHS in England for …
NICE approves lipid disorder drug Myalepta for NHS use
January 20, 2021Research and Development Amryt Pharma, NICE
NICE has approved Amryt’s rare lipid disorder drug Myalepta (metreleptin), currently the only leptin replacement therapy available, for use within …
NICE recommends cutting-edge lymphoma treatment for NHS use
January 19, 2021Manufacturing and Production Cancer, NICE
NHS clinicians in England will be able to consider a cutting-edge cancer treatment for some patients with a form of …
NICE recommends GSK’s ZEJULA for advanced ovarian cancer
January 15, 2021Medical Communications Cancer, GlaxoSmithKline, NICE
NICE has recommended the use of GlaxoSmithKline’s ZEJULA (niraparib) on the NHS in England for adult women with advanced high-grade …
NICE recommends AstraZeneca’s FORXIGA for heart failure
January 7, 2021AstraZeneca, NICE
NICE has issued a positive Final Appraisal Document (FAD) recommending AstraZeneca’s FORXIGA (dapagliflozin) as an option for treatment of symptomatic …
Shionogi’s novel antibiotic selected for UK pilot subscription reimbursement model
December 21, 2020Sales and Marketing NICE, Shionogi, antibiotic
Japanese pharmaceutical company Shionogi today announced that NICE and NHS England and Improvement (NHSE&I) have selected its novel antibiotic Fetcroja …
NICE recommends GSK’s Nucala for more asthma patients
December 18, 2020Medical Communications GlaxoSmithKline, NICE, asthma, mepolizumab
NICE has today published final draft guidance recommending GlaxoSmithKline’s Nucala (mepolizumab) as an add-on treatment option for severe refractory eosinophilic …
NICE recommends Novartis’ Beovu for wet age-related macular degeneration
December 16, 2020Research and Development NICE, Novartis, wet AMD Beovu
NICE has published its final appraisal of Novartis’ Beovu (brolucizumab), recommending that the drug be made available via the NHS …
NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine
December 11, 2020Medical Communications, Sales and Marketing Aimovig, NICE, Novartis, migraine
NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic …
NICE authorises Takeda’s Alunbrig for ALK-positive advanced non-small cell lung cancer
December 10, 2020Sales and Marketing ALK-positive advanced non-small cell lung cancer, Alunbrig, NICE, Takeda
NICE has published its final appraisal of Takeda’s Alunbrig (brigatinib), recommending the therapy for the treatment of ALK-positive advanced non-small …
Latest content
FibroFind appoints Lee Borthwick as CEO
